STAAR Surgical Company: appoints chief commercial officer

What happened

• The filing says STAAR Surgical Company announced that it appointed David Bailey as chief commercial officer, effective Sep 8, 2026.
• The filing says Mr. Bailey executed an offer letter that provides a base salary of CHF 462,825 (approximately $575,000) at an annual rate, prorated for 2026, and eligibility for the company’s annual cash bonus program with a target bonus for fiscal 2026 of 60% of his base salary, prorated for 2026.
• The filing says the equity component includes an initial equity grant valued at $850,000 (50% restricted stock units and 50% stock options) with RSUs vesting over three years (one-third on each anniversary) and stock options vesting over three years, and a 2026 annual long-term incentive award valued at $1,400,000, prorated and issued 50% stock options and 50% RSUs.

Key details

• Appointment effective date: Sep 8, 2026.
• Base salary: CHF 462,825 (approximately $575,000) per year, prorated for 2026; bonus target: 60% of base, prorated for 2026.
• Initial equity grant: $850,000 (50% RSUs, 50% options); 2026 long-term incentive award: $1,400,000, prorated (50% options, 50% RSUs).
• Mr. Bailey previously served as the company’s chief executive officer & president (2001–2008) and president, international operations (2008–2011), and from 2010 was founder and president of DB Consulting.

Why it may matter

• The filing reports an Item 5.02 event (departure of directors or certain officers; election of directors) covering the appointment of an officer and also includes Regulation FD disclosure under Item 7.01.
• The filing says Mr. Bailey will participate in the company’s executive compensation, benefits plans, and standard severance and change in control terms, and that the Bailey Agreement is filed as Exhibit 10.1.
• The filing does not show why the insider traded or why the company acted.